Rheumatoid Arthritis - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Rheumatoid Arthritis - Drug Pipeline Analysis and Market Forecasts to 2015”. The report is an essential source of information and analysis on the global Rheumatoid Arthritis (RA) market. The report identifies the key trends shaping and driving the global RA market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global RA sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by the team of industry experts.

Scope

The scope of the report includes:

• Annualized global rheumatoid arthritis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes CD targetters, THF dehydrogenase targetters, TNF targetters, COX targetters, Interleukin targetters, kinase targetters, and Cytokine targetters other than TNF.

• Analysis of the current and future market competition in the global rheumatoid arthritis market. Key market players covered are Pfizer Inc., Roche, Biogen Idec, Amgen Inc. and Mitsubishi Tanabe Pharma.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with rheumatoid arthritis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global rheumatoid arthritis market.

• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global rheumatoid arthritis market in future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

• What’s the next big thing in the global rheumatoid arthritis market landscape? - Identify, understand and capitalize.

 

1

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis Market: Market Characterization

2.1 Overview

2.2 Rheumatoid Arthritis Market Size

2.3 Rheumatoid Arthritis Market Forecast and CAGR

2.4 Drivers and Barriers for Rheumatoid Arthritis Market

2.4.1 Drivers for Rheumatoid Arthritis Market

2.4.2 Barriers for Rheumatoid Arthritis Market

2.5 Opportunity and Unmet Need

2.6 Key Takeaway

3 Rheumatoid Arthritis Market: Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profile for the Major Marketed Products in Rheumatoid Arthritis Market

3.3.1 Enbrel (etanercept)

3.3.2 Humira (adalimumab)

3.3.3 Remicade (infliximab)

3.3.4 Rituxan (rituximab)

3.3.5 Celebrex (celecoxib)

3.4 Product Profile for the Major Marketed Products in Rheumatoid Arthritis Market

3.4.1 Enbrel (etanercept)

3.4.2 Humira (adalimumab)

3.4.3 Remicade (infliximab)

3.4.4 Rituxan (rituximab)

3.4.5 Celebrex (celecoxib)

3.5 Key Takeaway

4 Rheumatoid Arthritis Market: Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.2.1 Technology Trends Analytic Framework

4.3 Rheumatoid Arthritis Therapeutic -Promising Drugs under Clinical Development

4.4 Molecule Profile for Promising Drugs under Clinical Development for Rheumatoid Arthritis

4.4.1 T-614 (iguratimod)

4.4.2 CP-690550

4.4.3 Ocrelizumab (Humanized Anti-CD20 mAb)

4.4.4 Arzerra (HuMax-CD20 /Ofatumumab)

4.4.5 PN 400 (VIMOVO)

4.5 Rheumatoid Arthritis Therapeutics Market - Clinical Pipeline by Mechanism of Action

4.6 Rheumatoid Arthritis Pipeline - Pipeline by Clinical Phases of Development

4.6.1 Rheumatoid Arthritis Therapeutics - Regulatory and Phase III Clinical Pipeline

4.6.2 Rheumatoid Arthritis Therapeutics-Phase II Clinical Pipeline

4.6.3 Rheumatoid Arthritis Therapeutics-Phase I Clinical Pipeline

4.6.4 Rheumatoid Arthritis Therapeutics- Preclinical Pipeline

4.6.5 Rheumatoid Arthritis Therapeutics- Discovery Pipeline

4.7 Discontinued / Suspended Drugs for Rheumatoid Arthritis

4.8 Key Takeaway

5 Rheumatoid Arthritis Market: Implications for Future Market Competition

6 Rheumatoid Arthritis Market: Future Players in the Rheumatoid Arthritis Market

6.1 Introduction

6.2 Pfizer

6.2.1 Overview

6.2.2 Autoimmune and Musculoskeletal Portfolio

6.2.3 Rheumatoid Arthritis Product Portfolio

6.3 Roche

6.3.1 Overview

6.3.2 Autoimmune and Musculoskeletal Portfolio

6.3.3 Rheumatoid Arthritis Product Portfolio

6.4 Amgen

6.4.1 Overview

6.4.2 Autoimmune and Musculoskeletal Portfolio

6.4.3 Rheumatoid Arthritis Product Portfolio

6.5 Biogen idec

6.5.1 Overview

6.5.2 Autoimmune and Musculoskeletal Portfolio

6.5.3 Rheumatoid Arthritis Product Portfolio

6.6 Mitsubishi Tanabe

6.6.1 Overview

6.6.2 Autoimmune and Musculoskeletal Portfolio

6.6.3 Rheumatoid Arthritis Product Portfolio

7 Rheumatoid Arthritis Market:Appendix

7.1 Market Definitions

7.2 Abbreviations

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panels Validation

7.4 Contact Us

7.5 Disclaimer

7.6 Sources

1.1 List of Tables

Table 1: Global Rheumatoid Arthritis Therapeutics Market, Revenue ($bn), 2000-2008

Table 2: Global Rheumatoid Arthritis Therapeutics Market, Revenue ($bn), 2009-2015

Table 3: Major Marketed Products Comparison in Rheumatoid Arthritis Market, 2009

Table 4: Rheumatoid Arthritis Therapeutics - Most Promising Drugs under Clinical Development, 2009

Table 5: Rheumatoid Arthritis Therapeutics - Regulatory and Phase III Clinical Pipeline, 2009

Table 6: Rheumatoid Arthritis Therapeutics - Phase II Clinical Pipeline, 2009

Table 7: Rheumatoid Arthritis Therapeutics - Phase I Clinical Pipeline, 2009

Table 8: Rheumatoid Arthritis Therapeutics - Preclinical Pipeline, 2009

Table 9: Rheumatoid Arthritis Therapeutics - Discovery Pipeline, 2009

Table 10: List of Discontinued Drugs for Rheumatoid Arthritis, 2009

Table 11: Pfizer - Autoimmune and Musculoskeletal Marketed Products, 2009

Table 12: Pfizer - Autoimmune and Musculoskeletal Pipeline Products, 2009

Table 13: Roche - Autoimmune and Musculoskeletal Marketed Products, 2009

Table 14: Roche - Autoimmune and Musculoskeletal Pipeline Products, 2009

Table 15: Amgen - Autoimmune and Musculoskeletal Marketed Products, 2009

Table 16: Amgen - Autoimmune and Musculoskeletal Pipeline Products, 2009

Table 17: Biogen - Autoimmune and Musculoskeletal Marketed Products, 2009

Table 18: Biogen - Autoimmune and Musculoskeletal Pipeline Products, 2009

Table 19: Mitsubishi Tanabe - Autoimmune and Musculoskeletal Marketed Products, 2009

Table 20: Mitsubishi Tanabe - Autoimmune and Musculoskeletal Pipeline Products, 2009

1.2 List of Figures

Figure 1: Global Rheumatoid Arthritis Market Revenue ($m), 2000-2015

Figure 2: Opportunity and Unmet Need in the Rheumatoid Arthritis Market,2009

Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Rheumatoid Arthritis, 2009

Figure 4: Technology Trends Analytic Framework of the Rheumatoid Arthritis Pipeline, 2009

Figure 5: Technology Trends Analytic Framework of the Rheumatoid Arthritis Pipeline - Description, 2009

Figure 6: Rheumatoid Arthritis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2009

Figure 7: Rheumatoid Arthritis Pipeline by Phase of Clinical Development, 2009

Figure 8: Implications for Future Market Competition in the Rheumatoid Arthritis, 2009

Figure 9: Rheumatoid Arthritis Therapeutics Market - Clinical Pipeline by Company, 2009

Figure 10: GlobalData Methodology

Figure 11: GlobalData Market Forecasting Model